Prime Therapeutics recently entered into an outcomes-based contract with Boehringer Ingelheim as part of its CareCentered Contracting program. The collaboration is for Jardiance (empagliflozin), an oral type 2 diabetes medicine indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.   This CareCentered Contracting agreement will focus on the total cost of care for members taking Jardiance and comparing that to the total ...